This company has been acquired
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
TCR2 Therapeutics 過去の業績
過去 基準チェック /06
TCR2 Therapeutics's earnings have been declining at an average annual rate of -16%, while the Biotechs industry saw earnings growing at 32.7% annually.
主要情報
-16.0%
収益成長率
87.3%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -161.0% |
| ネット・マージン | n/a |
| 前回の決算情報 | 31 Mar 2023 |
最近の業績更新
更新なし
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10収支内訳
TCR2 Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -163 | 41 | 91 |
| 31 Dec 22 | 0 | -152 | 39 | 84 |
| 30 Sep 22 | 0 | -119 | 38 | 77 |
| 30 Jun 22 | 0 | -115 | 39 | 72 |
| 31 Mar 22 | 0 | -107 | 39 | 65 |
| 31 Dec 21 | 0 | -100 | 37 | 59 |
| 30 Sep 21 | 0 | -91 | 34 | 57 |
| 30 Jun 21 | 0 | -81 | 32 | 50 |
| 31 Mar 21 | 0 | -73 | 25 | 49 |
| 31 Dec 20 | 0 | -67 | 22 | 46 |
| 30 Sep 20 | 0 | -61 | 22 | 42 |
| 30 Jun 20 | 0 | -58 | 18 | 43 |
| 31 Mar 20 | 0 | -53 | 20 | 37 |
| 31 Dec 19 | 0 | -97 | 18 | 33 |
| 30 Sep 19 | 0 | -96 | 16 | 31 |
| 30 Jun 19 | 0 | -100 | 13 | 25 |
| 31 Mar 19 | 0 | -107 | 11 | 22 |
| 31 Dec 18 | 0 | -62 | 9 | 17 |
| 30 Sep 18 | 0 | -55 | 9 | 13 |
| 31 Dec 17 | 0 | -15 | 5 | 8 |
質の高い収益: TCRR is currently unprofitable.
利益率の向上: TCRR is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: TCRR is unprofitable, and losses have increased over the past 5 years at a rate of 16% per year.
成長の加速: Unable to compare TCRR's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: TCRR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
株主資本利益率
高いROE: TCRR has a negative Return on Equity (-160.96%), as it is currently unprofitable.